Baxter International Stock Hits New 52-Week High (BAX)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Baxter International (NYSE: BAX) hit a new 52-week high Wednesday as it is currently trading at $66.82, above its previous 52-week high of $66.70 with 196,700 shares traded as of 9:35 a.m. ET. Average volume has been 2.8 million shares over the past 30 days.

Baxter International has a market cap of $35.69 billion and is part of the health care sector and health services industry. Shares are up 31.5% year to date as of the close of trading on Tuesday.

Baxter International Inc., through its subsidiaries, develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The company has a P/E ratio of 15.8, below the S&P 500 P/E ratio of 17.7.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Baxter International as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, notable return on equity, growth in earnings per share, expanding profit margins and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full Baxter International Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!.
null

If you liked this article you might like

Gold Is Great Again Thanks to North Korea's Kim Jong-Un

J&J Enters Death Penalty Debate, Protests Use of Drug in Lethal Injection

Blue Apron, Philip Morris, Honeywell, Becton Dickinson: 'Mad Money' Lightning Round

Buy These High-Octane Stocks on a Dip: Cramer's 'Mad Money' Recap (Monday 8/7/17)

These Stocks Are Ready to Reverse Course